| Lung Cancer |
1 |
1 |
| KRAS |
0 |
0.99 |
| Biologic Therapy |
0 |
0.63 |
| Hepatocellular Carcinoma |
0 |
0.56 |
| Non-Small Cell Lung Cancer |
0 |
0.98 |
| Toxicology |
0 |
0.36 |
| Metastasis |
0 |
0.34 |
| Small Cell Lung Cancer |
0 |
0.3 |
| Cancer |
0 |
0.23 |
| Central Nervous System |
0 |
0.23 |
| Lung |
0 |
0.23 |
| Tumor |
0 |
0.17 |
| Board Certification |
0 |
0.12 |
| Chemotherapy |
0 |
0.12 |
| Drug Development |
0 |
0.12 |
| Immunotherapy |
0 |
0.12 |
| Diarrhea |
0 |
0.11 |
| Aminotransferase |
0 |
0.08 |
| Tyrosine Kinase Inhibitor |
0 |
0.08 |
| Brain |
0 |
0.06 |
| Cerebrospinal Fluid |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| Plasma |
0 |
0.06 |
| Platinum |
0 |
0.06 |
| Tyrosine Kinase |
0 |
0.06 |